EPIRUS Biopharmaceuticals, Inc. (EPRSQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) trades at $0.000001 with AI Score 46/100 (Grade C). EPIRUS Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing biosimilar therapeutics. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 1, 2026Analyst Coverage for EPRSQ: EPRSQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EPRSQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
EPRSQ: 1/2 scored disciplines lean bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) Healthcare & Pipeline Overview
EPIRUS Biopharmaceuticals, Inc. focused on developing biosimilar versions of established biologic drugs, targeting inflammatory diseases and ultra-rare blood disorders. Trading on the OTC market after filing for Chapter 7 liquidation, the company's future prospects are uncertain within the competitive biotechnology landscape.
What Is the Investment Thesis for EPRSQ?
Investing in EPIRUS Biopharmaceuticals (EPRSQ) presents significant risks due to its Chapter 7 bankruptcy filing and OTC market listing. The company's pipeline of biosimilar candidates, including versions of Remicade, Humira, Actemra, Soliris, and SIMPONI, offered potential value, but the company's financial instability casts doubt on its ability to bring these products to market. The company's beta is -14.11. Potential investors may want to evaluate the high degree of uncertainty and limited information available for companies in liquidation trading on the OTC market. The company's future is uncertain.
Based on FMP financials and quantitative analysis
EPRSQ Key Highlights
EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in July 2016.
- The company's lead product candidate was BOW015, a biosimilar version of Remicade (infliximab).
- EPIRUS had a pipeline of biosimilar candidates targeting inflammatory diseases and rare blood disorders.
- The company collaborated with Sun Pharmaceutical Industries Ltd., Livzon Mabpharm Inc., and Polpharma S.A.
- EPIRUS Biopharmaceuticals trades on the OTC market.
Who Are EPRSQ's Competitors?
EPRSQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EPRSQ's Key Strengths?
Pipeline of biosimilar candidates.
- Established partnerships.
- Expertise in biosimilar development.
What Are EPRSQ's Weaknesses?
Chapter 7 bankruptcy filing.
- OTC market listing.
- Limited financial resources.
What Are the Key Risks for EPRSQ?
Chapter 7 bankruptcy proceedings create substantial uncertainty about the company's future.
- Limited access to capital hinders the development and commercialization of biosimilar candidates.
- Intense competition in the biosimilars market could erode market share and profitability.
- Regulatory hurdles and delays in obtaining approvals for biosimilar products.
- OTC market listing increases volatility and reduces investor confidence.
What Are the Growth Opportunities for EPRSQ?
- Expansion of Biosimilar Pipeline: EPIRUS had the opportunity to expand its biosimilar pipeline by developing biosimilars for other blockbuster biologic drugs. The global biosimilars market is projected to reach $35.7 billion by 2027, presenting a significant growth opportunity. However, the company's bankruptcy status severely limits its ability to capitalize on this market. Timeline: Uncertain, dependent on restructuring and funding.
- Strategic Partnerships and Licensing: EPIRUS could pursue strategic partnerships and licensing agreements to accelerate the development and commercialization of its biosimilar candidates. Collaborations with larger pharmaceutical companies could provide access to capital, expertise, and distribution networks. The value of such partnerships would depend on the terms and the specific assets involved. Timeline: Uncertain, dependent on restructuring and finding suitable partners.
- Emerging Markets Penetration: EPIRUS could target emerging markets with its biosimilar products, where there is a greater need for affordable medicines. These markets offer significant growth potential due to increasing healthcare spending and a growing middle class. However, navigating regulatory hurdles and establishing distribution channels in these markets can be challenging. Timeline: Long-term, dependent on regulatory approvals and market access.
- Cost-Effective Manufacturing: EPIRUS could focus on developing cost-effective manufacturing processes to reduce the cost of its biosimilar products. This would enhance its competitiveness and improve its profit margins. Investing in advanced manufacturing technologies and optimizing supply chain management could help achieve this goal. Timeline: Ongoing, requires continuous improvement and investment.
- Regulatory Approvals and Market Access: Securing regulatory approvals for its biosimilar candidates and gaining market access in key markets is crucial for EPIRUS's growth. This requires navigating complex regulatory pathways and demonstrating biosimilarity to the reference products. Successful regulatory approvals would unlock significant market opportunities. Timeline: Dependent on clinical trial results and regulatory review processes.
What Are EPRSQ's Competitive Advantages?
- Biosimilar Development Expertise: EPIRUS has expertise in developing biosimilar versions of complex biologic drugs.
- Established Partnerships: The company has established partnerships with other pharmaceutical companies.
- Pipeline of Biosimilar Candidates: EPIRUS has a pipeline of biosimilar candidates targeting various diseases.
What Does EPRSQ Do?
Founded in 2011 and headquartered in Boston, Massachusetts, EPIRUS Biopharmaceuticals, Inc. aimed to develop, manufacture, and commercialize biosimilar therapeutics on a global scale. The company's strategy centered around creating biosimilar versions of blockbuster biologic drugs, offering potentially lower-cost alternatives to established treatments. Its lead product candidate was BOW015, a biosimilar version of Remicade (infliximab), used to treat inflammatory diseases. The pipeline also included BOW050 (biosimilar Humira), BOW070 (biosimilar Actemra), BOW080 (biosimilar Soliris), and BOW100 (biosimilar SIMPONI), targeting a range of inflammatory conditions and rare blood disorders. EPIRUS pursued collaborations and licensing agreements with companies like Sun Pharmaceutical Industries Ltd., Livzon Mabpharm Inc., and Polpharma S.A. to support its development and commercialization efforts. However, on July 25, 2016, the company filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts, leading to its current status on the OTC market.
What Products and Services Does EPRSQ Offer?
- Develop biosimilar versions of existing biologic drugs.
- Target inflammatory diseases and ultra-rare blood disorders.
- Manufacture biosimilar therapeutics.
- Commercialize biosimilar products globally.
- Seek regulatory approvals for biosimilar candidates.
- Collaborate with other pharmaceutical companies.
How Does EPRSQ Make Money?
- Develop and manufacture biosimilar drugs.
- Seek regulatory approval for their biosimilar products.
- Commercialize and distribute biosimilar drugs through partnerships and direct sales.
- Generate revenue through the sale of biosimilar products.
What Industry Does EPRSQ Operate In?
EPIRUS Biopharmaceuticals operated within the competitive biotechnology industry, specifically targeting the biosimilars market. Biosimilars offer lower-cost alternatives to established biologic drugs, driven by patent expirations and increasing healthcare cost pressures. The market is characterized by intense competition, stringent regulatory requirements, and the need for significant investment in research and development. Companies like Amgen, Sandoz, and Mylan are major players in the biosimilars space. EPIRUS's bankruptcy filing highlights the challenges faced by smaller companies in this capital-intensive industry.
Who Are EPRSQ's Key Customers?
- Patients with inflammatory diseases.
- Patients with ultra-rare blood disorders.
- Healthcare providers.
- Hospitals and clinics.
- Pharmacies.
Company Profile
EPIRUS Biopharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Jeff Kagy. EPRSQ has traded publicly since 2005.
EPRSQ Valuation & Market Position
Relative to its peer group, EPRSQ's quantitative score of 46/100 is below the peer average of 76/100.
EPRSQ Financials
Bull Case vs Bear Case
Bull Case
- Pipeline of biosimilar candidates.
- Established partnerships.
- Expertise in biosimilar development.
Bear Case
- Chapter 7 bankruptcy filing.
- OTC market listing.
- Limited financial resources.
- Ongoing: Chapter 7 bankruptcy proceedings create substantial uncertainty about the company's future.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
EPRSQ Latest News
No recent news available for EPRSQ.
EPRSQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EPRSQ.
Price Targets
Wall Street price target analysis for EPRSQ.
EPRSQ MoonshotScore
What does this score mean?
The MoonshotScore rates EPRSQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jeff Kagy
Unknown
Information about Jeff Kagy's background is not available in the provided data. Therefore, his career history, education, and previous roles are Unknown.
Track Record: Information about Jeff Kagy's track record is not available in the provided data. Therefore, his key achievements, strategic decisions, and company milestones under his leadership are Unknown.
EPRSQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that do not meet the listing requirements of OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, be undergoing bankruptcy proceedings, or face regulatory issues. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Bankruptcy status.
- Low liquidity.
- Wide bid-ask spreads.
- Potential for delisting.
- Verify the company's current legal status.
- Review any available financial statements.
- Assess the liquidity and trading volume.
- Understand the risks associated with OTC Other stocks.
- Consult with a financial advisor.
- Research the company's history and management team.
- Confirm the company's disclosure status.
- The company was founded in 2011.
- EPIRUS Biopharmaceuticals had partnerships with established pharmaceutical companies.
- The company developed a pipeline of biosimilar candidates.
What Investors Ask About EPIRUS Biopharmaceuticals, Inc. (EPRSQ) — Healthcare
What does the AI Score mean for EPRSQ?
EPRSQ holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. EPIRUS Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing biosimilar therapeutics. The company filed for liquidation under Chapter 7 bankruptcy …
What does EPIRUS Biopharmaceuticals, Inc. do?
EPIRUS Biopharmaceuticals, Inc. was focused on developing, manufacturing, and commercializing biosimilar therapeutics. The company aimed to create biosimilar versions of established biologic drugs, offering potentially lower-cost alternatives. Its pipeline included biosimilar candidates for inflammatory diseases and ultra-rare blood disorders. However, the company filed for Chapter 7 liquidation in 2016 and currently trades on the OTC market, significantly impacting its operational capabilities.
What do analysts say about EPRSQ stock?
Given EPIRUS Biopharmaceuticals' Chapter 7 bankruptcy filing and OTC market listing, formal analyst coverage is likely limited or non-existent. Key valuation metrics are difficult to assess due to the company's financial instability. Investors should exercise extreme caution and conduct thorough due diligence before considering an investment in EPRSQ. The company's growth prospects are uncertain.
What are the main risks for EPRSQ?
The primary risks for EPRSQ stem from its Chapter 7 bankruptcy filing and OTC market listing. These include limited financial disclosure, low liquidity, wide bid-ask spreads, and the potential for delisting. The company's ability to continue operations and develop its biosimilar pipeline is highly uncertain. Investors face a significant risk of losing their entire investment.
What are the key factors to evaluate for EPRSQ?
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) holds an AI score of 46/100 (low). Investing in EPIRUS Biopharmaceuticals (EPRSQ) presents significant risks due to its Chapter 7 bankruptcy filing and OTC market listing. Not financial advice.
How frequently does EPRSQ data refresh on this page?
EPRSQ's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven EPRSQ's recent stock price performance?
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Pipeline of biosimilar candidates. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EPRSQ overvalued or undervalued right now?
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research EPRSQ before investing?
Before investing in EPIRUS Biopharmaceuticals, Inc. (EPRSQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's bankruptcy status and OTC market listing.
- Financial data may not be current or reliable.
- The company's future is highly uncertain.